Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.

@article{Nakajima2006ImpactOT,
  title={Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.},
  author={Yukiko Nakajima and Takashi Yoshitani and Hiromi Fukushima-Uesaka and Yoshiro Saito and Nahoko Kaniwa and Kouichi Kurose and Shogo Ozawa and Nobuo Aoyagi and Naoyuki Kamatani and Noboru Yamamoto and Hideo Kunitoh and Yuichiro Ohe and Tomohide Tamura and Teruhiko Yoshida and Hironobu Minami and Nagahiro George Saijo and Noriko Katori and Jun-ichi Sawada},
  journal={Clinical pharmacology and therapeutics},
  year={2006},
  volume={80 2},
  pages={179-91}
}
OBJECTIVE Paclitaxel is one of the most important anticancer drugs for the treatment of various tumors such as non-small cell lung cancer. We investigated the association between CYP3A4 haplotypes and pharmacokinetic parameters of paclitaxel metabolism. METHODS This study enrolled 235 Japanese patients with cancer who were receiving paclitaxel. These patients were screened for CYP3A4 gene polymorphisms by either direct sequencing or pyrosequencing. Plasma concentrations of paclitaxel and its… CONTINUE READING
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…